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Abstract With recent studies showing increased prevalence
of hepatitis delta (HDV) even in the US, Australia, and some
countries in Europe, and very high prevalence in endemic
regions, HDV infection is far from being a disappearing
disease. Although immigrants from endemic countries have
been shown to have increased risk, studies have clearly shown
that the disease is not solely appearing in traditional high-risk
groups. Recent studies provide increasing evidence that sex-
ual transmission may be an important factor in HDV infection
spread. Based on the totality of evidence showing increased
disease progression and substantially increased risk of cirrho-
sis in HDV-infected CHB patients, and the current studies
showing higher than expected prevalence, it is time to call
for HDV screening of all CHB patients. HDV viral load
detection and measurement should be considered in all pa-
tients whether or not they are anti-HDV-positive. With uni-
versal screening of CHB patients for HDV, earlier diagnosis
and consideration of treatment would be possible. Current
treatment of HDV is IFN-based therapy with or without
HBV antivirals, but current research indicates the possibility
that prenylation inhibitors, entry inhibitors, HBsAg release
inhibitors, or other therapies currently in the pipeline may
provide more effective therapy in the future. In addition,
universal screening would serve the important public health
goal of allowing patients to be educated on their status and on
the need for HDV-negative patients to protect themselves
against superinfection and for HDV-infected patients to pro-
tect against transmission to others. Further studies and global
awareness of HDV infection are needed.
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BEA Baseline Event-Anticipation
CHB cChronic hepatitis B
chol-siRNA cCholesterol-conjugated siRNA
HBsAg hHepatitis B surface antigen
HBV hHepatitis B virus
HCC hHepatocellular carcinoma
HDV Hepatitis Delta virus
NAG-MLP N-acetylgalactosamine-conjugated
melittin-like peptide
NAP nNucleic acid-based amphipathic polymer
Peg-IFN pPegylated interferon




Hepatitis delta virus (HDV) was first discovered in 1977 by
Mario Rizzetto in Turin, Italy [1]. Collaboration between
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Turin and US scientists on experiments in chimps demonstrat-
ed that the delta antigen requires HBV for its ability to infect
hepatocytes [2–4]. HDV is the smallest human RNA virus
with a small circular RNA genome of approximately 1,700
bases; the genome is single-stranded negative sense and forms
a covalently closed circle [5]. Because of a large amount of
base pairing, the viral RNA takes on a rod-like structure. The
RNA then encodes a protein called the delta antigen, which is
subsequently encased in an envelope embedded with hepatitis
B surface antigen (HBsAg) [5]. HDV infection is significant
because, although it suppresses hepatitis B virus (HBV) rep-
lication, it can cause severe liver disease that may include
fulminant liver failure and rapid progression to cirrhosis and
hepatic decompensation, as well as an increased risk of liver
cancer. Since HDV can only cause infection in the presence of
HBV, it was thought that the widespread introduction of HBV
vaccine would ultimately result in decreased prevalence of
HDV. However, current studies have shown that ongoing high
prevalence remains in many parts of the world.
Prevalence
It was long ago established that HDV is found throughout the
world, with higher prevalence in countries with populations of
low socioeconomic status in Africa and South America, as
well as in Turkey, Mongolia, southern Italy, and the Soviet
Union [6]. HDV antibodies were found in up to 30 % of
chronic hepatitis B (CHB) patients in some of these countries
[7]. On the other hand, there was a lower prevalence in CHB
patients in northern Europe and North America, with HDV
infection thought to be mainly restricted to intravenous drug
users [4, 7]. In the second decade after discovery, there was a
decrease in prevalence of HDV which was thought to be
mainly the result of the implementation of the HBV vaccine
[8]. This led to decreased awareness and testing for HDV
which further contributed to the perception that the virus
was on its way to being eradicated [8]. Unfortunately, recent
studies have shown the contrary.
In the United States, a recent study found that 8 % of CHB
patients in northern California were coinfected with HDV
[9••]. Interestingly, 73 % of the coinfected patients had cirrho-
sis compared to 17 % of patients who were only HBV infect-
ed. In addition, 63 % of these patients were born in North
America and only 26 % reported past IV drug use, showing
that the disease is not solely appearing in immigrants and drug
users. These findings clearly emphasize the importance of
HDV screening of all CHB patients, not just those with
established risk factors or cirrhosis. However, drug use is
clearly still a major risk factor, with a study from Baltimore
showing 50 % HDV coinfection in CHB patients who are IV
drug users [10].
Worldwide, it is estimated that 15–20 million people are
HDV infected, with widely varying prevalence, depending on
the region [7, 11]. The highest prevalence is seen in the
Mediterranean basin, the Middle East, central and northern
Asia, western and central Africa, the Amazonian basin (Brazil,
Peru, Venezuela, and Colombia), the Pacific islands [12], and
Vietnam [13]. In a recent study in the western Brazilian
Amazon region, 41.9 % of HBsAg-positive patients were
found to be coinfected with HDV, with prevalence over
60 % among individuals aged 20–39 years [14]. The higher
prevalence in this age group suggests the likelihood of sexual
transmission. In a 2013 study from West Africa (Mauritania),
it was found that up to 30 % of CHB patients had anti-HDV
antibodies [15]. Among these, 62.2 % were HDV-RNA-
positive. A recent study from the Middle East showed that,
in Zahedan, Iran, 17% of CHB patients were positive for anti-
HDV antibodies [16]. A recent meta-analysis showed that
14.8 % of asymptomatic HBsAg-positive patients in the east-
ern Mediterranean region are coinfected with HDV and that
cirrhosis is common in this group [17]. A recent study in
Vietnam showed HDV prevalence of 10.7 % in CHB patients
[13], a prevalence much higher than expected since previous
studies had shown either very low levels of HDV infection in
Vietnamese CHB patients [18] or none at all [19]. These
studies confirm the continuing high prevalence of HDV in-
fection in the Amazonian basin, the Middle East, the eastern
Mediterranean region, and western Africa, and show the un-
expectedly high prevalence in Vietnam. At the other end of the
prevalence scale, a recent report from Egypt showed that
4.7 % of CHB patients are coinfected with HDV [20]. In a
study in India which assessed 450 CHB patients for coinfec-
tion with HIV or HDV, it was found that 4.8 % were HBV/
HDV-coinfected, while only 1.5 % were HIV/HBV-
coinfected and 0.8 % were HBV/HDV/HIV-tri-infected [21].
However, HBV/HDV coinfection was substantially higher
(45.8 %) in patients aged 21–40 years old. Again, the higher
prevalence in this age group suggests that the transmission of
HDV could be due to sexual transmission.
In Europe, where HDV had been thought to be decreasing,
studies in 2013 showed a trend toward increasing prevalence.
In a large prospective Greek study which has followed 4,673
CHB patients from 1997 to the present, of the 2,137 patients
who have been screened for HDV, 4.2 % were found to be
anti-HDV-positive, with substantially greater prevalence seen
in immigrants (7.5 %) than in native Greeks (2.8 %). The
study showed that HDV testing decreased substantially over
time, dropping from 57 % prior to 2003 to only 35.3 %
thereafter [22]. Within 2.3 years of follow-up, new HDV
infection occurred in 2.2 adults and 8.7 children per 1,000
HBsAg-positive patients annually. A study from Belgium
showed that 5.5 % of CHB patients are HDV-coinfected, a
prevalence that is higher than previously reported [23]. In
London, the prevalence of HDV infection was found to be
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2 % among CHB patients [24]. The majority of HDV-infected
patients were either IV drug users or immigrants. In compar-
ison, other European countries were found to have substan-
tially higher prevalence in some populations, with coinfection
reported in 20.4 % of CHB patients in Bucharest, Romania,
and 20.9% of 1,220 CHB immigrants from Equatorial Guinea
living in Spain [25, 26].
Finally, an important Australian study found that of the 2,
314 Victoria residents tested for HDV infection from 2000 to
2009, 110 (4.75 %) were found to be HDV-infected [27]. Both
the number of people testing positive and the number of tests
conducted steadily increased between 2005 and 2009. The
majority of cases were immigrants (71.4 %) and male (77 %).
The investigators concluded that their findings emphasize the
need for routine HDV testing of all CHB patients. We agree,
and believe that, since HDV coinfection results in worse
disease, including cirrhosis at younger age, the continuing
high prevalence in many countries, and trend toward increas-
ing prevalence in some parts of the world, these clearly point
to the need to revise screening guidelines to call for HDV
screening in all CHB patients. With multiple studies showing
particularly high prevalence in immigrants from endemic
countries, they should be considered as being at particularly
high risk of being infected.
Clinical Course
The transmission of HDV can occur sexually (via semen or
vaginal secretions), through blood (needle stick injuries, in-
jection drug use, and transfusions), and perinatally. Recent
studies provide increasing evidence that sexual transmission
may be a more important factor in the spread of the disease
than has previously been appreciated. The studies discussed
above that found substantially higher prevalence of HDV
coinfection in patients aged 20–39 years (60 % vs. an overall
prevalence of 41.9 %) [14] and in 21–40 year olds (45.8 % vs.
an overall prevalence of 4.8 %) [21] highlight the importance
of sexual transmission and point to the need to first screen
patients and then educate HDV-negative patients about the
need for protection against superinfection and HDV-infected
patients about the need to protect against transmission to
others.
HDV can be transmitted only in the existence of concom-
itant HBV infection as one of two patterns, simultaneous
HBV/HDV infection (coinfection) or HDV infection of an
individual already chronically infected with HBV
(superinfection). The coinfection pattern ranges from mild to
severe or fulminant hepatitis [28]. Coinfection is usually self-
limited, with 20% of cases progressing to cirrhosis. However,
coinfection can lead to more severe fulminant hepatitis com-
pared to superinfection [29]. Superinfection may present as
exacerbation of disease in previously asymptomatic CHB
patients, worsening of disease in CHB patients, or as acute
hepatitis [29]. Superinfection is usually confirmed with posi-
tive HDVantibodies and negative IgM anti-HBc [29]. Chronic
hepatitis D is acquired in 90 % of superinfection cases and
leads to cirrhosis in 5–10 years in 70 % of the patients.
Cirrhosis incidence is three times higher with HDV infection
than with HBV monoinfection [29]. Cirrhosis may continue
for many years, but a high percentage of patients will decom-
pensate, develop hepatocellular carcinoma (HCC), and/or re-
ceive liver transplantation [30]. HCC association with chronic
HDV is still controversial, with some studies showing up to a
three-fold increase in risk and others showing no increase
[30]. Pathogenicity can influence outcome in HDV infection
and may vary between genotypes [31]. At least 8 genotypes of
HDV have been described. Genotype I has been found in the
United States, Europe, the Middle East, North America, and
North Africa. Genotype II has been found in the Far East,
Genotype III in South America, and Genotypes IV–VIII in
Africa [31].
Diagnosis
With the high prevalence in many countries already discussed,
including the surprisingly high prevalence in the US despite
its longstanding HBV vaccination programs, and the trends
toward increasing prevalence in some parts of the world, it
seems more than reasonable to advocate for all CHB patients
to be screened for HDV infection. With multiple studies
showing particularly high prevalence in immigrants from
endemic countries, they should be considered as being at
particularly high risk of being infected, and consideration
should be given to the development of programs to reach this
population. There should absolutely be testing of all members
of high-risk groups, including injection drug users, men who
have sex with men, hemodialysis patients, anyone who has
sexual contact with confirmed HDV-infected persons, and
health-care and public safety workers. Patients with chronic
HBV who experience clinical deterioration should also be
tested [32].
HDV antigen can be measured; however, it is only tran-
siently detectable in serum. The detection of HDVantibodies
in HBsAg-positive patients is usually the initial step in the
diagnosis of HDV; however, these antibodies can be falsely
negative. Recently, there has been an emphasis on testing for
HDV RNA viral load as more laboratories have gained expe-
rience in measuring it. To date, this method has mostly been
done in academic centers.
It is not yet commercially available in the US, although the
PCR test is becoming more available in some other countries
[33•, 34]. In the US, a one-step TaqMan quantitative reverse
transcription polymerase chain reaction (qRT-PCR) assay has
been developed for detection of HDV RNA, which has been
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found to be highly reliable and accurate in detecting viral load
[35]. It is likely that viral load testing will be available soon in
the US in commercial laboratories, and, in the meantime, all
efforts should be made to send samples, especially with sus-
pect populations, to laboratories experienced in measuring
viral load. Any physician or associated medical personnel
can submit specimens to the CDC for HDV testing if the
person is suspected of having HDV. The specimens should
be packaged in accordance with the CDC requirements for
shipping biological specimens (http://www.cdc.gov/hepatitis/
HEV/PDFs/HRL_PCRSampleHndlgShpg_20080615.pdf)
and must be accompanied by the form from this link
completed in its entirety: http://www.cdc.gov/hepatitis/HDV/
index.htm.
In HDV-positive patients, it is critical to distinguish acute
HDVand HBV infection (coinfection) from HDV superinfec-
tion in CHB patients, since the prognosis and management are
different. Acute infection with HDV concomitant with acute
infection with HBVusually appears first as IgM anti-HDVand
then converts to IgG anti-HDV; HDV RNA levels reach high
levels in the serum. HBV IgM anti-HBc will also be found to
be positive in this acute HDV/HBV coinfection. In superin-
fection, HDVantibodies appear early as IgM, followed by IgG
anti-HDV, whereas anti-HBc is IgG only. Both HDV and
HBV antibodies may increase in superinfection as the HDV
disease progresses to chronicity, and may be present in high
titers along with positive HDV RNA. Finally, a Baseline
Event-Anticipation (BEA) score has been developed to pre-
dict the risk of development of liver-related complications
(decompensation, hepatocellular carcinoma, liver transplanta-
tion, and/or death) in chronic HDV patients [36•]. This easy to
apply clinical instrument uses age, gender, region of origin,
INR, platelet number, and bilirubin to calculate the score.
Factors associated with a poor long-term outcome include
age above 40, male sex, low platelet counts, high bilirubin,
elevated INR, and southeast Mediterranean origin.
Treatment
To date, the unique HDV replication cycle and its association
with HBV have led to difficulties in treatment regimens and
inadequate response rates. The ultimate approach for eradica-
tion of HDV is the clearance of HBsAg, not just sustained
HDV virological response (negative HDV RNA 6 months
after stopping treatment) [37]. If HBsAg remains positive,
HDV remains infectious, even if the HBVor HDV viral titers
are low. This has led to the concept that eradication of HBsAg
might also clear HDV infection. However, despite inhibition
of HBV replication and, in some cases, HBsAg clearance, the
clearance of HDV has not been seen when oral antivirals
against HBV were used alone. Lamivudine, ribavirin,
famciclovir, adefovir, and entecavir have shown little or no
effect when used alone to treat HDV, regardless of the duration
of treatment [38–42].
Interferon-alpha is the only therapy that has been shown to
be at least somewhat effective for treatment of HDV (Table 1),
leading to virological, biochemical, and histological response
in some patients. Weekly injection of PEG-IFN-a is currently
used for 12–18 months. A 2013 review concluded that recent
trials have shown HDV SVRs in 25–30 % of patients treated
with pegylated interferons (Peg-IFN) [43]. However, in one of
the few trials with truly long-term follow-up, Heidrich and
colleagues found that even in patients who are HDV-RNA-
negative 6 months after Peg-IFN-based treatment, late re-
lapses may occur [44••]. In their initial study, Peg-IFN alfa-
2a treatment for 48 weeks, with or without adefovir, resulted
in 28 % of the patients having undetectable HDV-RNA
6 months post-treatment [42]. Long-term follow-up data were
available for 37 of the 60 patients treated with Peg-IFN, with a
median time of follow-up of approximately 4 years. Of the 16
patients entering the follow-up study who were HDV-RNA-
negative 6 months after treatment, half (8 individuals) tested
HDV-RNA-positive at least once during further follow-up,
leading the investigators to call for close monitoring of pa-
tients post-Peg-IFN therapy, even in patients who are HDV-
RNA-negative 6 months after therapy completion [44••].
HDV may relapse if HBsAg remains positive [40]. In a
long ago trial of IFN-alfa-2a therapy that compared no treat-
ment to high-dose (9 million units) and low-dose (3 million
units) IFN, given 3 times a week for 48 weeks, 50 % of the
high-dose group had a complete response defined by bio-
chemical response (normalization of ALT) in addition to
virological response (negative HDV levels at the end of the
treatment) , compared to no complete response in any of those
in the low-dose or no-treatment groups. Although sustained
clearance of HDV RNAwas not maintained in the high-dose
group following cessation of therapy, a long-term follow-up
study (up to 12 years) demonstrated significantly improved
survival and liver histology [45]. More recently, Peg-IFN has
been increasingly used because of its longer half-life, which
allows once weekly dosing. Although no head-to-head com-
parison trials have been carried out, two major reviews have
not been able to definitively show that either type of IFN
therapy is superior to the other. Although one recent system-
atic review of randomized trials found that 1 year of high-dose
interferon-alpha monotherapy achieved higher levels of unde-
tectable HDV RNA and normalization of ALT at the end of
treatment when compared with Peg-IFN-alpha monotherapy
(RR 4.14; 95 % CI 1.00–17.14), levels of HDV RNA sup-
pression 24 weeks after the end of therapy were not signifi-
cantly different [46]. Another systematic review comparing
standard and Peg-IFN-alpha found pooled sustained virologic
response rates of 19 and 29 % of patients, respectively [47].
However, the investigators were unable to reach definitive
conclusions on superiority due to the variation in trial designs
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involving standard IFN and the small number of patients
involved. In other studies, the combination of Peg-IFN with
ribavirin or with adefovir has been compared to treatment with
Peg-IFN alone [42, 48]. The combinations yielded no differ-
ence in SVR rate, although the combination of Peg-IFN and
adefovir resulted in increased decline in HBsAg levels. Ex-
tending the duration of Peg-IFN therapy has shown no effect
on response rate [49]. In a study from Turkey, 32% of patients
with advanced chronic liver disease achieved virological re-
sponse with Peg-IFN treatment and there was no significant
Table 1 Outcomes of interferon therapy
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EOT: HDV RNAwas negative in 23 % in the
first group, 24 % in the second, and none in the third
SVR: 28 % in the 1st and 2nd groups and none
in the 3rd group.
A decline in HBsAg levels of more than 1
log(10) IU /mL observed in 10/31 patients in the first
group, 2/29 in the second, and none in the third
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difference in treatment response between patients with ad-
vanced and non-advanced chronic liver disease [50]. Acute
HDV hepatitis has been more challenging to treat. Patients
with fulminant hepatitis have had no response to IFN-alpha
therapy, and liver transplant is the only option for fulminant
hepatic failure resulting from coinfection or superinfection
with HDV [51].
Future Treatment
There are several current areas of research that may ultimately
lead to important HDV treatment advances. Prenylation of the
last four amino acids on the large-HDAg (the so-called CXXX
box) is important for the interaction of HDV antigen with
HBsAg [43, 52, 53]. Many small-molecule inhibitors of pro-
tein farnesyltransferase (which plays a role in prenylation)
have been developed. These molecules compete with CXXX
peptide substrates or with farnesyl diphosphate [43]. Both
in vitro and in vivo studies have demonstrated that inhibition
of prenylation results in clearance of HDV infection. Current-
ly, the National Institutes of Health is enrolling HDV patients
in a double-blinded, randomized, placebo-controlled trial to
investigate the effectiveness of 4 weeks of treatment with the
prenylation inhibitor lonafarnib, an oral farnesyltransferase
inhibitor, with post-therapy follow up for a total of 6 months
to assess for a sustained virological response (http://www.
cl inical t r ia ls .gov/ct2/show/NCT01495585?term=
lonafarnib&rank=11).
Myclurdex, an HBV entry inhibitor, may also hinder
the establishment of HDV infection by breaking the
cycle of hepatocyte infection and possibly re-infection
[54]. REP 9AC is a nucleic acid-based amphipathic
polymer (NAP) which inhibits the release of HBsAg
from infected hepatocytes. REP 9AC is currently being
evaluated in patients with chronic HBV in a proof-of-
concept clinical trial. Interim data showed that seven out
of eight patients treated with REP 9AC cleared HBsAg
or had only residual levels [55, 56]. Clearance of
HBsAg and development of anti-HBs occurred as early
as 7 days and no later than 32 weeks. Since HDV
requires HBsAg for complete replication and transmis-
sion, REP 9AC might ultimately become an important
new treatment tool.
New research on RNA interference (RNAi)-based thera-
pies shows that they may also have the potential to treat HBV/
HDV coinfection. In recent proof-of-concept studies, it was
shown that, in transient and transgenic mouse models,
coinjection of a hepatocyte-targeted, N-acetylgalactosamine-
conjugated melittin-like peptide (NAG-MLP) with a liver-
tropic cholesterol-conjugated siRNA (chol-siRNA) targeting
conserved HBV sequences yielded multilog repression of
viral RNA, proteins, and viral DNA [57]. With production
of HBsAg blocked via RNA interference, HDV viral release
might be decreased or prevented, potentially allowing im-
mune control to overtake viral replication and effect viral
clearance [58–60]. Finally, in the same way that we can
currently use changes in levels of cytokines such as IP10 to
monitor patients’ responses to standard interferon therapy, we
may in future be able to map cytokine levels in order to
monitor responses to new immunotherapy agents used as
treatments for HBVand HDV, such as lambda interferon and
TLR7 agonists.
Conclusion
HDV infection is far from being a disappearing disease.
Studies have shown increased prevalence even in devel-
oped countries, including the US, Australia, and some
countries in Europe, and very high prevalence in endem-
ic regions, despite the implementation of widespread
HBV vaccination. Immigrants from endemic countries
have been shown to have increased risk. Recent studies
provide increasing evidence that sexual transmission may
be an important factor in the spread of HDV infection.
Based on the totality of evidence showing increased
disease progression and substantially increased risk of
cirrhosis in CHB patients who are also infected with
HDV, and the current studies showing higher than ex-
pected prevalence, it is time to call for HDV screening of
all CHB patients. HDV viral load detection and measure-
ment should be considered in all patients whether or not
they are anti-HDV-positive. With universal screening of
CHB patients for HDV, earlier diagnosis and consider-
ation of treatment would be possible. Current treatment
of HDV is IFN-based therapy with or without HBV
antivirals, but current research indicates the possibility
that prenylation inhibitors, entry inhibitors, HBsAg re-
lease inhibitors, or the other therapies currently in the
pipeline discussed here may provide more effective ther-
apy in the future. In addition, universal screening would
serve the important public health goal of allowing pa-
tients to be educated on their status and on the need for
HDV-negative patients to protect themselves against su-
perinfection, and for HDV-infected patients to protect
against transmission to others. Further studies and global
awareness of HDV infection are needed.
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